© 2022 MJH Life Sciences and Center for Biosimilars®. All rights reserved.
© 2022 MJH Life Sciences™ and Center for Biosimilars®. All rights reserved.
January 4th 2022
By Tony Hagen
Savings from adalimumab biosimilars, which won't enter the US market until 2023, account for a significant share of the total, investigators said.
January 1st 2022
Biosimilars have produced more than $20 billion of savings in Europe, but more use of these agents is needed.
December 21st 2021
The year 2021 brought several firsts in biosimilars and set the stage for expansion across therapeutic areas including diabetes and ophthalmology.
December 16th 2021
Alvotech has received European Commission (EC) approval to begin marketing its adalimumab biosimliar AVT02, the company announced this week.
Investigators said more evidence would help to convince clinicians of the safety of switching between biosimilar products.
December 15th 2021
Xbrane Biopharma of Stockholm, Sweden, said its next biosimilar candidates will target the demand for oncology and hematology therapeutics.
December 6th 2021
Henlius gains approval in China for Hanbeitai and officials discuss combination therapy options with experimental therapy serplulimab and ophthalmology treatment.
December 2nd 2021
By Meir Rinde, MS
Researchers report findings that suggest a different reimbursement system for Medicare Part B biologics could lead to significantly more robust savings.
December 1st 2021
In the second setback this year for etanercept biosimilars, the US District Court for the District of New Jersey has ordered Samsung Bioepis to delay marketing Eticovo until 2029.
November 30th 2021
Regulators are at work clarifying biosimilar guidance and on Capitol Hill, a battle is raging over reforms that could help or hurt biosimilar advancement.